Here’s the BBC’s take on the news about the South Africa variant: bbc.co.uk/news/uk-559677…
@AstraZeneca “expressed confidence that the vaccine would offer protection against serious cases, because it created neutralising antibodies similar to those of other coronavirus vaccines.”
@AstraZeneca “expressed confidence that the vaccine would offer protection against serious cases, because it created neutralising antibodies similar to those of other coronavirus vaccines.”
https://twitter.com/fact_covid/status/1358157667752161286
Nevertheless the preliminary findings, first reported by the Financial Times and since confirmed by AstraZeneca, do suggest the vaccine offers only limited protection against mild and moderate disease caused by the variant.
The study is due to be published tomorrow.
The study is due to be published tomorrow.
The @UniofOxford told Reuters it was working with AstraZeneca to optimise the pipeline in vaccine production if it needed to adapt to a change in the virus.
It has said a new vaccine to work against mutated versions of the virus could be ready to deploy in the autumn, if needed.
It has said a new vaccine to work against mutated versions of the virus could be ready to deploy in the autumn, if needed.
Whilst this development is not ideal, we shouldn’t be alarmed just yet.
And we already know the Oxford-AstraZeneca vaccine gives people good protection against the B1.1.7 coronavirus variant which is now dominant in the UK.
And we already know the Oxford-AstraZeneca vaccine gives people good protection against the B1.1.7 coronavirus variant which is now dominant in the UK.
So @whippletom has managed to get hold of the data before the preprint is published. He’s put together a useful thread here:
https://twitter.com/whippletom/status/1358467319824080896
• • •
Missing some Tweet in this thread? You can try to
force a refresh
